• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 433068 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418869527 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418869527 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Sell Off Shares of Halozyme Therapeutics, Down 12.4%

Published on Thu, 01/31/2013 - 11:13
By Peter Chu

Halozyme Therapeutics (NASDAQ:HALO) is one of today's biggest movers, down 12.4% to $6.21. The S&P is trading fractionally lower to 1,501 and the Dow is trading fractionally higher to 13,918.

Halozyme Therapeutics has overhead space with shares priced $6.21, or 37.4% below the average consensus analyst price target of $9.92. The stock should find initial resistance at its 50-day moving average (MA) of $6.61 and further resistance at its 200-day MA of $7.09.

Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $13.50 and is now at $6.21, 61% above that low. The 200-day and 50-day moving averages have moved 0.67% lower and 2.40% higher over the past week, respectively.

Halozyme Therapeutics, Inc. develops and commercializes recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The Company's product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's products offer an alternative to slaughterhouse-derived extracts that carry contamination risks.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of ViewPoint Financial Fall to a ...

ViewPoint Financial (NASDAQ:VPFG) traded today at a new 52-week low of $21.11. This ne ...

Shares of UQM Technologies Have Fallen B...

Shares of UQM Technologies (AMEX:UQM) traded at a new 52-week low today of $0.86. Appr ...

Shares of Terex Have Fallen Below Previo...

Shares of Terex (NYSE:TEX) traded at a new 52-week low today of $25.40. So far today a ...

Sun Communities: The Winning Streak Cont...

Shares of Sun Communities (NYSE:SUI) traded at a new 52-week high today of $60.92. So ...

Watch for Continued Losses in Shares of ...

Renesola (NYSE:SOL) traded today at a new 52-week low of $1.21. Approximately 1.1 mill ...

Solera Holdings Looks to Continue to Tra...

Solera Holdings (NYSE:SLH) traded today at a new 52-week low of $45.69. Approximately ...

SAIFUN SEMICONDUCTOR Looks to Continue t...

SAIFUN SEMICONDUCTOR (NASDAQ:SFUN) traded today at a new 52-week low of $6.78. So far ...

Shares of Select Comfort Rise Above Prev...

Shares of Select Comfort (NASDAQ:SCSS) traded at a new 52-week high today of $27.13. T ...